転移性肺腺がん治療市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント別予測、2025年～2030年

転移性肺腺がん治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の転移性肺腺がん治療市場規模は2030年までに92億9,000万米ドルに達し、2025～2030年のCAGRは11.3％で拡大すると推定されます。

この拡大には、有病率の上昇、治療技術の進歩、規制や政府の支援策など、いくつかの重要な要因があります。世界保健機関（WHO）によると、肺がんは依然として世界的に最も多く診断されるがんで、毎年約250万人が新たに罹患し、新規がん罹患者全体の12.4％を占めます。この高い罹患率は、効果的な治療法に対する緊急の需要を強調しています。

最近の治療動向は市場開拓に大きく貢献しています。ALK阻害剤やEGFR阻害剤を含む標的治療などの革新は、転移性肺腺がんの管理に革命をもたらしました。例えば、2024年3月にPfizer社が第3相CROWN検査の長期追跡データを発表しました。この検査では、新たにALK陽性進行非小細胞肺がん（NSCLC）と診断された患者を対象に、第三世代ALK阻害剤であるLORBRENAの有効性をXALKORIと比較して評価しました。ロルブレナ（ロルラチニブ）やタグリッソ（オシメルチニブ）などの薬剤は、患者に新たな希望をもたらし、生存率やQOLの改善につながります。さらに、チェックポイント阻害剤のような免疫療法の採用が増加しており、治療の選択肢はさらに広がっています。

市場の成長を促進する上で、規制機関は重要な役割を果たしています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの機関は、有望な治療法に対して迅速な承認プロセスを導入しており、新しい治療法への患者のアクセスを加速させています。さらに、米国のNational Cancer Moonshot Initiativeや欧州連合（EU）のHorizon Europeプログラムなどの政府のイニシアチブが研究資金を提供し、新規治療法の開発を支援しており、市場の拡大と転移性肺腺がんに対する治療選択肢の開拓に貢献しています。

転移性肺腺がん治療市場レポートハイライト

• 治療に基づき、市場は化学療法、標的療法、免疫療法、放射線療法、その他に区分されます。2024年、化学療法セグメントは転移性肺腺がん治療市場において36%の最大収益シェアを占めました。
• 病院セグメントは、2024年に63.9%の最大収益シェアを占めます。病院は一般的に先進的診断・治療設備を備えており、複雑ながん治療に適した環境となっています。
• 北米の転移性肺腺がん治療市場は、高い疾患罹患率と技術革新の重視によって牽引されています。肺がん、特に腺がんの罹患率の増加は、腫瘍の遺伝子プロファイルに合わせたより個別化された治療戦略の採用につながりました。
• 標的治療セグメントは、がんの特定の分子ドライバーを正確に標的とする能力により、2025～2030年にかけてCAGR 12.9%を記録し、最も急成長するセグメントとして浮上すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 転移性肺腺がん治療市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析

第4章 転移性肺腺がん治療市場：治療ビジネス分析

• 治療市場シェア、2024年と2030年
• 治療セグメントダッシュボード
• 市場規模と予測と動向分析、治療別、2018～2030年
• 化学療法
• 標的療法
• 免疫療法
• 放射線治療
• その他

第5章 転移性肺腺がん治療市場：最終用途ビジネス分析

• 最終用途市場シェア、2024年と2030年
• 最終用途セグメントダッシュボード
• 市場規模と予測と動向分析、最終用途別、2018～2030年
• 病院
• 専門クリニック
• その他

第6章 転移性肺腺がん治療市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Pfizer Inc.
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Merck KGaA（EMD Serono）
  • F. Hoffmann-La Roche Ltd
  • GSK plc.
  • AbbVie Inc.

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. Global Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 4. Global Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 5. Global Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 6. North America Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 7. North America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 8. North America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 9. U.S. Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 10. U.S. Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 11. Canada Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 12. Canada Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 13. Mexico Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 14. Mexico Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 15. Europe Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 16. Europe Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 17. Europe Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 18. UK Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 19. UK Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 20. Germany Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 21. Germany Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 22. France Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 23. France Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 24. Spain Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 25. Spain Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 26. Italy Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 27. Italy Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 28. Denmark Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 29. Denmark Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 30. Sweden Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 31. Sweden Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 32. Norway Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 33. Norway Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 34. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 35. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 36. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 37. China Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 38. China Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 39. Japan Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 40. Japan Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 41. India Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 42. India Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 43. South Korea Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 44. South Korea Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 45. Australia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 46. Australia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 47. Thailand Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 48. Thailand Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 49. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 50. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 51. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 52. Brazil Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 53. Brazil Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 54. Argentina Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 55. Argentina Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 56. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 57. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 58. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 59. South Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 60. South Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 61. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 62. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 63. UAE Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 64. UAE Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 65. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 66. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Metastatic Lung Adenocarcinoma Treatment Market Segmentation
• Fig. 2 Market Research Process
• Fig. 3 Data Triangulation Techniques
• Fig. 4 Primary Research Pattern
• Fig. 5 Market Research Approaches
• Fig. 6 Value-Chain-Based Sizing & Forecasting
• Fig. 7 Market Formulation & Validation
• Fig. 8 Market Snapshot
• Fig. 9 Treatment and End Use Outlook (USD Million)
• Fig. 10 Competitive Landscape
• Fig. 11 Metastatic Lung Adenocarcinoma Treatment Market Dynamics
• Fig. 12 Metastatic Lung Adenocarcinoma Treatment Market: Porter's Five Forces Analysis
• Fig. 13 Metastatic Lung Adenocarcinoma Treatment Market: PESTLE Analysis
• Fig. 14 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Segment Dashboard
• Fig. 15 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Market Share Analysis, 2024 & 2030
• Fig. 16 Chemotherapy Market, 2018 - 2030 (USD Million)
• Fig. 17 Targeted Therapy Market, 2018 - 2030 (USD Million)
• Fig. 18 Immunotherapy Market, 2018 - 2030 (USD Million)
• Fig. 19 Radiation Therapy Market, 2018 - 2030 (USD Million)
• Fig. 20 Others Market, 2018 - 2030 (USD Million)
• Fig. 21 Metastatic Lung Adenocarcinoma Treatment Market: End Use Segment Dashboard
• Fig. 22 Metastatic Lung Adenocarcinoma Treatment Market: End Use Market Share Analysis, 2024 & 2030
• Fig. 23 Hospitals Market, 2018 - 2030 (USD Million)
• Fig. 24 Specialty Clinics Market, 2018 - 2030 (USD Million)
• Fig. 25 Others Market, 2018 - 2030 (USD Million)
• Fig. 26 Metastatic Lung Adenocarcinoma Treatment Market Revenue, By Region
• Fig. 27 Regional Marketplace: Key Takeaways
• Fig. 28 Regional Marketplace: Key Takeaways
• Fig. 29 North America Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 30 U.S. Country Dynamics
• Fig. 31 U.S. Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 32 Canada Country Dynamics
• Fig. 33 Canada Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 34 Mexico Country Dynamics
• Fig. 35 Mexico Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 36 Europe Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 37 UK Country Dynamics
• Fig. 38 UK Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 39 Germany Country Dynamics
• Fig. 40 Germany Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 41 France Country Dynamics
• Fig. 42 France Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 43 Spain Country Dynamics
• Fig. 44 Spain Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 45 Italy Country Dynamics
• Fig. 46 Italy Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 47 Denmark Country Dynamics
• Fig. 48 Denmark Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 49 Sweden Country Dynamics
• Fig. 50 Sweden Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 51 Norway Country Dynamics
• Fig. 52 Norway Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 53 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 54 Japan Country Dynamics
• Fig. 55 Japan Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 56 China Country Dynamics
• Fig. 57 China Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 58 India Country Dynamics
• Fig. 59 India Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 60 South Korea Country Dynamics
• Fig. 61 South Korea Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 62 Australia Country Dynamics
• Fig. 63 Australia Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 64 Thailand Country Dynamics
• Fig. 65 Thailand Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 66 Latin America Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 67 Brazil Country Dynamics
• Fig. 68 Brazil Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 69 Argentina Country Dynamics
• Fig. 70 Argentina Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 71 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 72 South Africa Country Dynamics
• Fig. 73 South Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 74 Saudi Arabia Country Dynamics
• Fig. 75 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 76 UAE Country Dynamics
• Fig. 77 UAE Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 78 Kuwait Key Country Dynamics
• Fig. 79 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
• Fig. 80 Company Categorization
• Fig. 81 Company Market Position Analysis
• Fig. 82 Strategic Framework

Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends:

The global metastatic lung adenocarcinoma treatment market size is estimated to reach USD 9.29 billion by 2030, expanding at a CAGR of 11.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

• Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2024, the chemotherapy segment accounted for the largest revenue share of 36% in metastatic lung adenocarcinoma treatment market
• The hospital segment accounts for the largest revenue share of 63.9% in 2024. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
• The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors
• The targeted therapy segment is anticipated to emerge as the fastest-growing segment and register a CAGR of 12.9% from 2025 to 2030, owing to its ability to target specific molecular drivers of cancer precisely.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 4.7. Radiation Therapy
  • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
• 4.8. Other
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamic
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamic
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamic
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamic
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamic
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamic
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamic
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Spain Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Italy
    • 6.5.6.1. Key Country Dynamic
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Italy Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamic
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamic
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Norway Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamic
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamic
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamic
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamic
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamic
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamic
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamic
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamic
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamic
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamic
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamic
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamic
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamic
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Pfizer Inc.
    • 7.5.1.1. Participant's Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Eli Lilly and Company
    • 7.5.2.1. Participant's Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. AstraZeneca
    • 7.5.3.1. Participant's Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Bristol-Myers Squibb Company
    • 7.5.4.1. Participant's overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Boehringer Ingelheim International GmbH
    • 7.5.5.1. Participant's Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Novartis AG
    • 7.5.6.1. Participant's Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Merck KGaA (EMD Serono)
    • 7.5.7.1. Participant's Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. F. Hoffmann-La Roche Ltd
    • 7.5.8.1. Participant's Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. GSK plc.
    • 7.5.9.1. Participant's Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. AbbVie Inc.
    • 7.5.10.1. Participant's Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives